Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.23.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]    
Revenues
Operating Expenses:    
Research and development 1,650,000 2,087,000
Selling, general and administrative (including $718 and $447 from stock compensation granted to officers, directors and employees during the three months ended March 31, 2023 and 2022, respectively) 2,015,000 3,355,000
Loss from Operations 3,665,000 5,442,000
Other (Income) Expense    
Interest income (164,000) (8,000)
Interest expense 212,000
Change in fair value of warrant liability (2,924,000) (18,000)
Gain on extinguishment of debt (533,000)
Unrealized (gain) loss on marketable securities (29,000) 24,000
Total Other (Income) Expense (3,438,000) (2,000)
Net Loss $ (227,000) $ (5,440,000)
Net Loss Per Share - Basic and Diluted $ (0.01) $ (0.17)
Weighted average common shares outstanding - basic and diluted 39,085,515 32,486,116